Xpovio (selinexor)

Numéro de dossier de l’APP: 21962
État des négociations:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients, in combination with bortezomib (V) and dexamethasone (d), with multiple myeloma (MM) who have received at least one prior therapy.
Promoteur/fabricant:
Forus Therapeutics Inc.
Numéro de projet de l’ACMTS:
PC0276
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation:
Not Applicable